Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report. (PubMed, Cureus) - Dec 4, 2025 - "Initially, levodopa/benserazide was started at a dose of 500 mg/day and increased up to 1,000 mg/day. Amantadine at a dose of 200 mg/day and levodopa/carbidopa sustained release at a dose of 200/50 mg/day were added to the treatment regimen, but no effective clinical response was observed...This case highlights the subtle prodromal features and progressive course of PSP, emphasizing the importance of early recognition. It also contributes to the literature by illustrating the clinical progression and therapeutic challenges in managing PSP, underscoring the value of a multidisciplinary approach to optimize patient outcomes."
Journal • CNS Disorders • Progressive Supranuclear Palsy
|
|
Ibrahim Korucu; Tuba Karakoyun Alpay
|